Zuari Agro Chemicals Limited has settled a regulatory case with the Securities and Exchange Board of India concerning alleged misrepresentation of financial statements and lapses in approvals for related-party transactions. The settlement order, issued by the regulator, brings closure to adjudication proceedings initiated under various provisions of securities market regulations.

According to the regulator’s findings, the case relates to financial reporting practices during FY20 and governance procedures involving large transactions with group entities. The company and four senior officials collectively paid a settlement amount of ₹2.91 crore to resolve the matter under SEBI’s settlement framework. The order specifies that the settlement is made without admitting or denying the allegations. Details of the regulatory order can be accessed through the regulator’s public disclosure portal at.

The investigation centered on how the company accounted for an impairment charge of ₹117.79 crore related to its investments. SEBI alleged that the impairment was recorded in the comparative financial statements of FY19 instead of being reflected in FY20, the period in which the financial impact occurred. According to the show-cause notice, this accounting treatment resulted in an under-reporting of losses for FY20 and failed to properly disclose the financial effect in either the FY19 or FY20 statements.

In addition, the regulator questioned a slump sale transaction in which certain businesses were transferred to a wholly owned subsidiary. The transaction resulted in the booking of an exceptional gain of ₹698.97 crore in the company’s accounts. SEBI’s order indicated that the treatment of this gain masked the company’s actual financial position, raising concerns about the transparency and integrity of the financial reporting.

The regulator also identified governance lapses in relation to related-party transactions. Specifically, SEBI alleged that the company executed material transactions worth ₹811.33 crore with Paradeep Phosphates Limited without obtaining prior approval from the audit committee and shareholders as required under listing regulations. Such approvals are mandatory for material related-party transactions to ensure independent oversight and protect minority shareholder interests.

As part of the settlement terms, Zuari Agro Chemicals paid ₹1.19 crore and agreed to a voluntary three-month debarment from trading in securities. Senior executives also accepted financial penalties and temporary trading restrictions. Managing Director Sunil Sethy and Chief Financial Officer R K Gupta each paid ₹73.12 lakh and accepted a four-month voluntary ban from trading in securities. Whole-time Director Nitin Manguesh Kantak and Company Secretary Vijayamahantesh Khannur paid ₹12.67 lakh each.

SEBI initiated the proceedings under provisions of the SEBI Act, the listing regulations governing corporate disclosures, and the PFUTP regulations that address fraudulent and unfair trade practices in securities markets. The case was ultimately resolved through the regulator’s settlement mechanism following approval by its panel of whole-time members.

Settlement orders under SEBI’s framework do not represent a formal finding of guilt but allow entities to close regulatory proceedings by paying monetary penalties and accepting specified conditions. The regulator also clarified that it retains the right to reopen enforcement proceedings if it later determines that the settlement applicants failed to provide complete and accurate disclosures or violated commitments made as part of the settlement process.

From a corporate governance perspective, the case underscores the regulatory focus on transparency in financial reporting and stricter oversight of related-party transactions. Over the past decade, SEBI has strengthened disclosure requirements to ensure that listed companies properly reflect their financial performance and avoid accounting practices that could mislead investors.

For investors, the immediate financial impact of the settlement amount is relatively limited given the company’s balance sheet scale. However, governance-related developments often carry reputational implications that can influence investor perception and institutional confidence. Companies facing regulatory scrutiny typically experience heightened monitoring from shareholders and proxy advisory firms regarding board oversight and financial disclosure standards.

In the broader context of India’s capital markets, enforcement actions related to financial reporting reinforce SEBI’s ongoing effort to tighten compliance standards among listed entities. The regulator has increasingly scrutinized accounting practices, particularly those involving exceptional items, asset impairments, and intra-group transactions that may materially affect reported profits.